azacitidine has been researched along with Kidney Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, M; Levine, LB; Li, J; Phillips, G; Roddy, JV; Walker, AR | 1 |
| D'Haese, PC; Godderis, L; Moonen, L; Poels, K; Vervaet, BA | 1 |
| Ali, IY; Gupta, C; Gupta, J; Tikoo, K | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Poster, DS; Weiss, RB | 1 |
| Greenberg, MS | 1 |
| Anderson, K; Coleman, M; Cuttner, J; Schiffer, CA | 1 |
1 review(s) available for azacitidine and Kidney Diseases
| Article | Year |
|---|---|
The renal toxicity of cancer chemotherapeutic agents.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Cyclophosphamide; Dacarbazine; Humans; Kidney Diseases; Methotrexate; Mitomycins; Naphthacenes; Nitrosourea Compounds; Plicamycin; Streptozocin; Thioguanine | 1982 |
1 trial(s) available for azacitidine and Kidney Diseases
| Article | Year |
|---|---|
Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azacitidine administered by continuous infusion: a Cancer and Leukemia group B Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypotension; Infusions, Parenteral; Kidney Diseases; Leukemia, Myeloid; Male; Middle Aged | 1985 |
5 other study(ies) available for azacitidine and Kidney Diseases
| Article | Year |
|---|---|
A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; Comorbidity; Decitabine; Female; Humans; Kidney Diseases; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2018 |
Untargeted DNA-Demethylation Therapy Neither Prevents Nor Attenuates Ischemia-Reperfusion-Induced Renal Fibrosis.
Topics: Animals; Azacitidine; Collagen Type I; Cytokines; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Enzyme Inhibitors; Fibrosis; Kidney; Kidney Diseases; Kidney Tubules; Male; Mice; Mice, Inbred C57BL; Reperfusion Injury; Transforming Growth Factor beta | 2017 |
5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blood Urea Nitrogen; Blotting, Western; Breast Neoplasms; Cell Nucleus; Cisplatin; Colonic Neoplasms; Creatinine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Synergism; Drug Therapy, Combination; Female; Histones; Kidney Diseases; Male; Mammary Neoplasms, Experimental; Metallothionein; Neoplasms, Experimental; p38 Mitogen-Activated Protein Kinases; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley | 2009 |
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles | 2012 |
Reversible renal dysfunction due to 5-azacytidine.
Topics: Aged; Azacitidine; Female; Humans; Kidney Diseases; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged | 1979 |